I was going to post about this but got side-tracked for events regarding personal life.
The famous anti-PD-1 drug we have been talking more on the board is from Genentech, but Bristol-Myers has its own devlopment. It's called BMS-936558 nivolumab. They have patients with complete response (thank you to lohidoc for sending this one to me).
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Clin Cancer Res January 15, 2013 19; 462
Purpose: Results from the first-in-human phase I trial of the anti–programmed death-1 (PD-1) antibody BMS-936558 [nivolumab] in patients with treatment-refractory solid tumors, including safety, tolerability, pharmacodynamics, and immunologic correlates, have been previously reported. Here, we provide long-term follow-up on three patients from that trial who sustained objective tumor regressions off therapy, and test the hypothesis that reinduction therapy for late tumor recurrence can be effective.
Experimental Design: Three patients with colorectal cancer, renal cell cancer, and melanoma achieved objective responses on an intermittent dosing regimen of BMS-936558. Following cessation of therapy, patients were followed for more than 3 years. A patient with melanoma who experienced a prolonged partial regression followed by tumor recurrence received reinduction therapy.
Results: A patient with colorectal cancer experienced a complete response, which is ongoing after 3 years. A patient with renal cell cancer experienced a partial response lasting 3 years off therapy, which converted to a complete response, which is ongoing at 12 months. A patient with melanoma achieved a partial response that was stable for 16 months off therapy; recurrent disease was successfully treated with reinduction anti-PD-1 therapy.
Conclusion: These data represent the most prolonged observation to date of patients with solid tumors responding to anti-PD-1 immunotherapy and the first report of successful reinduction therapy following delayed tumor progression. They underscore the potential for immune checkpoint blockade with anti-PD-1 to reset the equilibrium between tumor and the host immune system.
full article: http://clincancerres.aacrjournals.org/c ... l.pdf+html
A good trial of this drug along with other (immunological too): Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors http://clinicaltrials.gov/ct2/show/NCT01629758
And this one (recruiting at some locations) that combines nivolumab and Ipilimumab (Yervoy, immunological agent approved for melanoma) for CRC:
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) http://clinicaltrials.gov/ct2/show/NCT02060188
(*the* one trial, lohidoc : targeting CTLA-4 and PD1/PD-L1)
This one, Nivolumab and Ipilimumab, is not for CRC but for other solid turmours, and it's recruiting; maybe one could check anyway:
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors http://clinicaltrials.gov/ct2/show/NCT01928394